The global market for In Situ Hybridization (ISH) at $4.3 billion in 2017 is anticipated to reach $7.8 billion by 2024 2017.  CAGR of 7.8% in the next five years (2017 to 2024). Increasing diagnosis and growing  incidence & prevalence of cancer, technology advancements in  therapeutics, increasing government initiatives globally are expected  to drive the growth of the market in the coming years.